Atazanavir concentration in hair is the strongest predictor of outcomes on antiretroviral therapy
about
The PHACS SMARTT Study: Assessment of the Safety of In Utero Exposure to Antiretroviral DrugsStrong relationship between oral dose and tenofovir hair levels in a randomized trial: hair as a potential adherence measure for pre-exposure prophylaxis (PrEP)Nevirapine Concentration in Hair Samples Is a Strong Predictor of Virologic Suppression in a Prospective Cohort of HIV-Infected PatientsEvidence for Reduced Drug Susceptibility without Emergence of Major Protease Mutations following Protease Inhibitor Monotherapy Failure in the SARA TrialLamivudine Concentration in Hair and Prediction of Virologic Failure and Drug Resistance among HIV Patients Receiving Free ART in ChinaQuantifying Isoniazid Levels in Small Hair Samples: A Novel Method for Assessing Adherence during the Treatment of Latent and Active TuberculosisHair and plasma data show that lopinavir, ritonavir, and efavirenz all transfer from mother to infant in utero, but only efavirenz transfers via breastfeedingUsing the multiphase optimization strategy (MOST) to optimize an HIV care continuum intervention for vulnerable populations: a study protocol.Genomewide association study of atazanavir pharmacokinetics and hyperbilirubinemia in AIDS Clinical Trials Group protocol A5202.A cross-sectional study to evaluate second line virological failure and elevated bilirubin as a surrogate for adherence to atazanavir/ritonavir in two urban HIV clinics in Lilongwe, Malawi.HIV-Infected Individuals Who Delay, Decline, or Discontinue Antiretroviral Therapy: Comparing Clinic- and Peer-Recruited CohortsAntiretroviral concentrations in small hair samples as a feasible marker of adherence in rural KenyaComparing the novel method of assessing PrEP adherence/exposure using hair samples to other pharmacologic and traditional measuresAssessment of HIV antiretroviral therapy adherence by measuring drug concentrations in hair among children in rural UgandaShort communication: Tenofovir diphosphate in dried blood spots as an objective measure of adherence in HIV-infected women.Efficacy and safety of lopinavir/ritonavir versus efavirenz-based antiretroviral therapy in HIV-infected pregnant Ugandan women.Hair concentrations of antiretrovirals predict viral suppression in HIV-infected pregnant and breastfeeding Ugandan women.Using Lopinavir Concentrations in Hair Samples to Assess Treatment Outcomes on Second-Line Regimens Among Asian Children.Implementation and Operational Research: Pulling the Network Together: Quasiexperimental Trial of a Patient-Defined Support Network Intervention for Promoting Engagement in HIV Care and Medication Adherence on Mfangano Island, KenyaAnalysis of Antiretrovirals in Single Hair Strands for Evaluation of Drug Adherence with Infrared-Matrix-Assisted Laser Desorption Electrospray Ionization Mass Spectrometry Imaging.Measuring the efficacy of antiretroviral therapyγ-H2AX and other histone post-translational modifications in the clinic.Behavioral intervention improves treatment outcomes among HIV-infected individuals who have delayed, declined, or discontinued antiretroviral therapy: a randomized controlled trial of a novel intervention.Hair Measurements of Cortisol, DHEA, and DHEA to Cortisol Ratio as Biomarkers of Chronic Stress among People Living with HIV in China: Known-Group ValidationA single-nucleotide polymorphism in CYP2B6 leads to >3-fold increases in efavirenz concentrations in plasma and hair among HIV-infected women.Microanalysis of the antiretroviral nevirapine in human hair from HIV-infected patients by liquid chromatography-tandem mass spectrometry.Menstrual cycle phase and single tablet antiretroviral medication adherence in women with HIV.Tenofovir, emtricitabine, and tenofovir diphosphate in dried blood spots for determining recent and cumulative drug exposure.Cohort for Tuberculosis Research by the Indo-US Medical Partnership (CTRIUMPH): protocol for a multicentric prospective observational studyEmerging antiretroviral drug resistance in sub-Saharan Africa: novel affordable technologies are needed to provide resistance testing for individual and public health benefits.Adherence profiles and therapeutic responses of treatment-naive HIV-infected patients starting boosted atazanavir-based therapy in the ANRS 134-COPHAR 3 trial.Reactions, beliefs and concerns associated with providing hair specimens for medical research among a South African sample: a qualitative approachIsoniazid hair concentrations in children with tuberculosis: a proof of concept studyCYP2B6*6 and CYP2B6*18 Predict Long-Term Efavirenz Exposure Measured in Hair Samples in HIV-Positive South African WomenAssociation of self-reported race with AIDS death in continuous HAART users in a cohort of HIV-infected women in the United StatesAntiretroviral bioanalysis methods of tissues and body biofluids.HIV PrEP Trials: The Road to Success.Short communication: A low-cost method for analyzing nevirapine levels in hair as a marker of adherence in resource-limited settings.Pharmacokinetics of lopinavir/ritonavir and efavirenz in food insecure HIV-infected pregnant and breastfeeding women in Tororo, Uganda.Multiphenotype association study of patients randomized to initiate antiretroviral regimens in AIDS Clinical Trials Group protocol A5202.
P2860
Q26744617-4B4D9D56-8D58-42A0-8BA5-07296E718D86Q28538457-8A3EC50B-5F59-4181-BF2E-9A528E090B1FQ28548003-1F79D5FE-7612-4AD4-8E64-7AB23B9A537FQ28548288-ADB0CE48-A79F-4D58-919B-F3D750B740C9Q28551633-9ED6814F-B76B-4098-B027-DDFC48EBE8A8Q28552186-1941937E-4CED-4C51-8572-FD72526CB1F2Q30679524-4A09C8A7-F4DE-4133-AB27-06BB214F710FQ33640486-B87D2478-5BF0-4175-BF85-928033366FA3Q33760652-59999023-6F9A-451D-BFEE-2D9DDA4B5A28Q33868639-5B472954-22D1-49E3-9B77-3904BF16A321Q33907350-D83ECC2E-8D16-47A1-9F3F-E47BB000E305Q34098406-D72DBCC2-3E04-43A1-A3A7-1EE0786DE3FEQ34675000-21500602-BAFD-49A7-875E-16F040750C1EQ35009569-1C30A209-BC32-4772-9110-1AFD65E30333Q35230243-5B7518CC-5D53-454F-B2C4-3BE190659F1CQ35597592-54C546A6-F4F7-4BA4-ABD9-03587D5046E0Q35627832-5A62C9F4-90BF-4BC9-A527-3C8562174272Q35705368-46B9345C-7A5F-4848-9C51-73ECDC229126Q35797968-C294C311-67FE-4716-AB82-A13C010E7FF5Q35873971-7CC6B360-7FC6-4613-9B5C-7BDA5729C4F1Q35983271-BDA2A394-223B-4BD9-BA70-CF7C06654F48Q36019818-99FE9B45-6401-4E0B-8DAD-A73CA85252FDQ36052895-954AB3EA-F6C5-41C4-91EB-CAE731F12F02Q36251231-6ED29D4C-EC75-434A-A81E-0810D8F44450Q36305444-44A25751-D6E3-4345-A0C0-3768EE6AFFA2Q36336929-2777B5EE-843A-4AC7-BB88-79DA746F4DDCQ36463574-62973286-47FA-4FCE-B403-A9C5EE3E5072Q36554980-9F2BF600-21FA-4732-BB7C-204044D5FD44Q36625240-9D53219F-FDA0-41CE-AD7E-34D0E49C12ECQ36669337-0EA72E9B-28C6-4154-A0FB-0396996FA900Q36785804-E12DA8BC-1F7D-40E9-8EA9-AB3A4BE6B666Q36808036-888FD459-1C93-4C1F-9618-13B4286059A1Q36958417-FC5C3204-9DED-4F88-9788-3360BAEB69C8Q36966640-3DD3D4E9-4231-4D44-8A71-0F7EA22D4FCEQ37272859-19095AE3-27BC-4566-B2BB-AC76E538A22EQ37332868-A4CF0F86-F1EF-47EB-B20B-3BB944806A98Q37438644-1B3337A9-0B20-4B89-99A2-6B6ABC241C24Q37460068-2BEC3491-ECAF-42F0-B737-C10CBB55098FQ37600844-1D5E3385-7561-41DA-8556-81F06DD1D6E4Q37617319-8A4A189F-F810-4AB1-AD65-3A33FA59AD7A
P2860
Atazanavir concentration in hair is the strongest predictor of outcomes on antiretroviral therapy
description
2011 nî lūn-bûn
@nan
2011 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Atazanavir concentration in ha ...... omes on antiretroviral therapy
@ast
Atazanavir concentration in ha ...... omes on antiretroviral therapy
@en
Atazanavir concentration in ha ...... omes on antiretroviral therapy
@nl
type
label
Atazanavir concentration in ha ...... omes on antiretroviral therapy
@ast
Atazanavir concentration in ha ...... omes on antiretroviral therapy
@en
Atazanavir concentration in ha ...... omes on antiretroviral therapy
@nl
prefLabel
Atazanavir concentration in ha ...... omes on antiretroviral therapy
@ast
Atazanavir concentration in ha ...... omes on antiretroviral therapy
@en
Atazanavir concentration in ha ...... omes on antiretroviral therapy
@nl
P2093
P2860
P356
P1476
Atazanavir concentration in ha ...... omes on antiretroviral therapy
@en
P2093
Gerald B Sharp
Howard Minkoff
Joel Milam
Kathryn Anastos
Mardge H Cohen
Mary Young
Monica Gandhi
Niloufar Ameli
Peter Bacchetti
Ruth M Greenblatt
P2860
P304
P356
10.1093/CID/CIR131
P407
P577
2011-05-01T00:00:00Z